Immunological considerations for embryonic and induced pluripotent stem cell banking
Authors:
- 12 August 2011
- journal article
- review article
- Published by The Royal Society in Philosophical Transactions of the Royal Society B: Biological Sciences
- Vol. 366 (1575) , 2312-2322
Abstract
Recent advances in stem cell technology have generated enthusiasm for their potential to study and treat a diverse range of human disease. Pluripotent human stem cells for therapeutic use may, in principle, be obtained from two sources: embryonic stem cells (hESCs), which are capable of extensive self-renewal and expansion and have the potential to differentiate into any somatic tissue, and induced pluripotent stem cells (iPSCs), which are derived from differentiated tissue such as adult skin fibroblasts and appear to have the same properties and potential, but their generation is not dependent upon a source of embryos. The likelihood that clinical transplantation of hESC- or iPSC-derived tissues from an unrelated (allogeneic) donor that express foreign human leucocyte antigens (HLA) may undergo immunological rejection requires the formulation of strategies to attenuate the host immune response to transplanted tissue. In clinical practice, individualized iPSC tissue derived from the intended recipient offers the possibility of personalized stem cell therapy in which graft rejection would not occur, but the logistics of achieving this on a large scale are problematic owing to relatively inefficient reprogramming techniques and high costs. The creation of stem cell banks comprising HLA-typed hESCs and iPSCs is a strategy that is proposed to overcome the immunological barrier by providing HLA-matched (histocompatible) tissue for the target population. Estimates have shown that a stem cell bank containing around 10 highly selected cell lines with conserved homozygous HLA haplotypes would provide matched tissue for the majority of the UK population. These simulations have practical, financial, political and ethical implications for the establishment and design of stem cell banks incorporating cell lines with HLA types that are compatible with different ethnic populations throughout the world.Keywords
This publication has 47 references indexed in Scilit:
- Evaluation of 28 Human Embryonic Stem Cell Lines for Use as Unrelated Donors in Stem Cell Therapy: Implications of HLA and ABO GenotypesCell Transplantation, 2010
- Transplantation tolerance through mixed chimerismNature Reviews Nephrology, 2010
- Epigenetic Mechanisms Regulate MHC and Antigen Processing Molecules in Human Embryonic and Induced Pluripotent Stem CellsPLOS ONE, 2010
- Adult stem cell transplantation in autoimmune diseaseCurrent Opinion in Hematology, 2009
- Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignanciesBlood, 2008
- Line of attack: NK cell specificity and integration of signalsCurrent Opinion in Immunology, 2008
- Embryonic stem cell-derived tissues are immunogenic but their inherent immune privilege promotes the induction of toleranceProceedings of the National Academy of Sciences, 2007
- Pathways of Helper CD4 T Cell Allorecognition in Generating Alloantibody and CD8 T Cell AlloimmunityTransplantation, 2007
- Human Embryonic Stem Cells Possess Immune‐Privileged PropertiesStem Cells, 2004
- Blood group isoantibody stimulation in man by feeding blood group-active bacteriaJournal of Clinical Investigation, 1969